Browsing by Author Wilcken, Nicholas

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
or enter first few letters:  
Showing results 1 to 20 of 55  next >
Issue DateTitleAuthor(s)Citation
20072-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial.Wilcken, Nicholas; Baselga, Jose (Prof); Bell, Richard (Prof); Bergh, Jonas (Prof); Cameron, David; Coleman, Robert; Dowsett, Mitch (Prof); Feyereislova, Andrea; Gelber, Richard D. (Prof); Gelmon, Karen (Prof); Goldhirsch, Aron (Prof); Guillaume, Sebastien; Harbeck, Nadia; Kaufmann, Manfred (Prof); Lopez, Roberto I; Mallmann, Peter (Prof); Mariani, Gabriella; Piccart-Gebhart, Martine J (Prof); Procter, Marion; Sanchez Rovira, Pedro; Smith, Ian (Prof); Untch, Michael (Prof); Wardley, Andrew; Wist, Erik (Prof); Western Clinical School: Medicine (Westmead)2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial., The Lancet, vol.369,(9555),2007,pp 29-36
2006Addition of drug/s to a chemotherapy regimen for metastatic breast cancerGhersi, Davina; Jones, D; Wilcken, Nicholas; NH&MRC Clinical Trials Centre; NH&MRC Clinical Trials Centre; Western Clinical School: Medicine (Westmead)Addition of drug/s to a chemotherapy regimen for metastatic breast cancer, Cochrane Database of Systematic Reviews, vol.19, 3, 2006,pp CD003368-CD003368
2006Addition of drug/s to a chemotherapy regimen for metastatic breast cancerGhersi, Davina; Jones, D; Wilcken, Nicholas; NH&MRC Clinical Trials Centre; NH&MRC Clinical Trials Centre; Western Clinical School: Medicine (Westmead)Addition of drug/s to a chemotherapy regimen for metastatic breast cancer, Cochrane Database of Systematic Reviews, vol.19, 3, 2006,pp CD003368-CD003368
2004Antitumour Antibiotic Containing Regimens For Metastatic Breast Cancer.Gattellari, Melina; Ghersi, Davina; Lord, Sarah (Sally); Thornton, Charlene; Wilcken, Nicholas; Simes, John; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials Centre; Western Clinical School: Medicine (Westmead)Antitumour Antibiotic Containing Regimens For Metastatic Breast Cancer., Cochrane Database of Systematic Reviews, vol.4,(CD003367),2004,pp 1-123
2012Cancer-Related Fatigue in Women With Breast Cancer: Outcomes of a 5-Year Prospective Cohort StudyBoyle, Frances; Hickie, Ian; Scott, Elizabeth; Wilcken, Nicholas; Bennett, Barbara; De Souza, P; Friedlander, Michael; Goldstein, David; Lloyd, Andrew R.; McCourt, Junie; Murie, Penelope; O'Malley, Linda; Toppler, Ruth; Webber, Kate; Northern Clinical School: Medicine; School of Medical Sciences: Brain & Mind Research Institute; School of Medical Sciences: Brain & Mind Research Institute; Western Clinical School: Medicine (Westmead)Cancer-Related Fatigue in Women With Breast Cancer: Outcomes of a 5-Year Prospective Cohort Study, Journal of Clinical Oncology, vol.30, 15, 2012,pp 1805-1812
2011Capecitabine Versus Classical Cyclophosphamide, Methotrexate, and Fluorouracil As First-Line Chemotherapy for Advanced Breast CancerCoates, Alan; Gebski, Val; Grimison, Peter; Stockler, Martin; Wilcken, Nicholas; Zannino, Diana; Ackland, Stephen; Byrne, Michael J.; Fitzharris, B; Fong, A.; Forbes, John; Francis, Prudence; Gainford, Corona; Harvey, V; Nowak, Anna; Paksec, Lisa; Simes, John; Sourjina, Tatiana; Van Hazel, Guy; School of Public Health: Public Health; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials Centre; Western Clinical School: Medicine (Westmead); School of Public Health: NH&MRC Clinical Trials CentreCapecitabine Versus Classical Cyclophosphamide, Methotrexate, and Fluorouracil As First-Line Chemotherapy for Advanced Breast Cancer, Journal of Clinical Oncology, vol.29, 34, 2011,pp 4498-4504
2003Chemotherapy for advanced breast cancer- how long should it continue?Coates, Alan; Stockler, Martin; Wilcken, Nicholas; School of Public Health: Public Health; School of Public Health: NH&MRC Clinical Trials Centre; Western Clinical School: Medicine (Westmead)Chemotherapy for advanced breast cancer- how long should it continue?, Breast Cancer Research and Treatment, vol.81,(Suppl 1),2003,pp S49-S52
2008Chemotherapy in metastatic breast cancer: A summary of all randomised trials reported 2000-2007Wilcken, Nicholas; Dear, Rachel; Western Clinical School: Medicine (Westmead)Chemotherapy in metastatic breast cancer: A summary of all randomised trials reported 2000-2007, European Journal of Cancer, vol.44,(15),2008,pp 2218-2225
2009Clinical recommendations for the use of lapatinib ditosylate plus capecitabine for patients with advanced or metastatic HER2-positive breast cancerWilcken, Nicholas; Boyle, Frances; Chan, Arlene; Craft, Paul; de Boer, Richard; Mainwaring, Paul; McCarthy, Nicole; Snyder, Raymond; Western Clinical School: Medicine (Westmead)Clinical recommendations for the use of lapatinib ditosylate plus capecitabine for patients with advanced or metastatic HER2-positive breast cancer, Asia Pacific Journal of Clinical Oncology, vol.5, 1,pp 4-16
2013Combination versus sequential single agent chemotherapy for metastatic breast cancerBarratt, Alexandra; Dear, Rachel; Jenkins, Marisa; McGeechan, Kevin; Tattersall, Martin; Wilcken, Nicholas; School of Public Health: Public Health; Central Clinical School: Medicine; School of Public Health: Public Health; School of Public Health: Public Health; Central Clinical School: Medicine; Western Clinical School: Medicine (Westmead)Combination versus sequential single agent chemotherapy for metastatic breast cancer, Cochrane Database of Systematic Reviews, vol.2013, 12, 2013,pp 1-91
2005Comparing patients' and their partners' preferences for adjuvant chemotherapy (ACT) in early breast cancer (EBC)Beith, Jane; Boyle, Frances; Butow, Phyllis; Coates, Alan; Duric, Vlatka; Heritier, Stephane; Sharpe, Louise; Simes, Robert John; Stockler, Martin; Wilcken, Nicholas; Central Clinical School: Medicine; Central Clinical School: Medicine; Psychology; School of Public Health: Public Health; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials Centre; Psychology; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials Centre; Western Clinical School: Medicine (Westmead)Comparing patients' and their partners' preferences for adjuvant chemotherapy (ACT) in early breast cancer (EBC), Journal of Clinical Oncology (Print), vol.23,(16S),2005,pp 546S-546S
2003Consensus on medical treatment of metastatic breast cancerStockler, Martin; Beslija, Semir; Bonneterre, Jacques; Burstein, Harold J.; Gnant, Michael; Goodwin, Pamela; Heinemann, Volker; Jassem, J; Köstler, Wolfgang; Krainer, Michael; Menard, Silvie; Miles, David; Petruzelka, Lubos; Possinger, Kurt; Schmid, Peter; Stadtmauer, Edward; Van Belle, Simon; Vogel, Charles; Wilcken, Nicholas; Wiltschke, Christoph; Zielinski, Christoph C.; Zwierzina, Heinz; School of Public Health: NH&MRC Clinical Trials CentreConsensus on medical treatment of metastatic breast cancer, Breast Cancer Research and Treatment, vol.81,(Supplement 1),2003,pp S1-S7
2016Dose escalation of tamoxifen in patients with low endoxifen level: Evidence for therapeutic drug monitoring - The TADE studyBalleine, Rosemary; Gao, Bo-Fu; Gebski, Val; Gurney, Howard; Hui, Rina; Kefford, Richard (Rick); Lee, Clara; Liddle, Christopher; Menzies, Alexander Maxwel; Provan, Pamela; Wilcken, Nicholas; Wong, Ka (Mark); Ali, Sayed Sahanawaz; Balakrishnar, Bavanthi; Coulter, Sally A.; Fox, Peter; Lynch, Jodi; Yeap, Shang Heng; Western Clinical School: Westmead Institute for Medical Res; Western Clinical School: Westmead Institute for Medical Res; NH&MRC Clinical Trials Centre; Western Clinical School: Medicine (Westmead); Western Clinical School: Medicine (Westmead); Western Clinical School: Westmead Institute for Medical Res; Western Clinical School (Westmead): Office; Western Clinical School: Medicine (Westmead); Central Clinical School: Medicine; Western Clinical School: Westmead Institute for Medical Res; Western Clinical School: Medicine (Westmead); Western Clinical School: Medicine (Westmead)Dose escalation of tamoxifen in patients with low endoxifen level: Evidence for therapeutic drug monitoring - The TADE study, Clinical Cancer Research, vol.22, 13, 2016,pp 3164-3171
2007Effect of sertraline on symptoms and survival in patients with advanced cancer, but without major depression: a placebo-controlled double-blind randomised trial.Beale, Philip; Carter, Candace; Dhillon, Haryana; Heritier, Stephane; Hickie, Ian; O'Connell, Rachel; Simes, Robert John; Stockler, Martin; Wilcken, Nicholas; Abdi, Ehtesham A; Glasgow, Amanda; Goldstein, David; Jefford, Michael; Nowak, Anna K.; Turner, Jane; Wyld, David; Central Clinical School: Medicine; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials Centre; Central Clinical School: Brain & Mind Research Institute; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials Centre; Western Clinical School: Medicine (Westmead)Effect of sertraline on symptoms and survival in patients with advanced cancer, but without major depression: a placebo-controlled double-blind randomised trial., Lancet Oncology, vol.8,(7),2007,pp 603-612
2016The 'enablers': inhibitors of mTOR, PI3K and CDK that prolong endocrine sensitivityWilcken, Nicholas; Western Clinical School: Medicine (Westmead)The 'enablers': inhibitors of mTOR, PI3K and CDK that prolong endocrine sensitivity, Cancer Forum, vol.40, 3, 2016,pp 1-4
2017Fulvestrant for hormone-sensitive metastatic breast cancerGoodwin, Annabel; Lee, Clara; Wilcken, Nicholas; Concord Clinical School: Medicine; Western Clinical School (Westmead): Office; Western Clinical School: Medicine (Westmead)Fulvestrant for hormone-sensitive metastatic breast cancer, Cochrane Database of Systematic Reviews, vol.2017, 1, 2017,pp 1-59
2012High-Risk Estrogen-Receptor-Positive Breast Cancer: Identification and Implications for TherapyBalleine, Rosemary; Wilcken, Nicholas; Western Clinical School: Westmead Millennium Institute; Western Clinical School: Medicine (Westmead)High-Risk Estrogen-Receptor-Positive Breast Cancer: Identification and Implications for Therapy, Molecular Diagnosis and Therapy, vol.16, 4, 2012,pp 235-240
2016Hope, optimism and survival in a randomised trial of chemotherapy for metastatic colorectal cancerPavlakis, Nick; Simes, Robert John; Stockler, Martin; Wilcken, Nicholas; Wong, Nicole; Burns, Ivon; Jefford, Michael; Moylan, Eugene; Price, Timothy; Ransom, David; Schofield, Penelope; Tebbutt, Niall; Underhill, Craig; Ward, R; Wyld, David; Zannino, Diana; Northern Clinical School: Medicine; NH&MRC Clinical Trials Centre; NH&MRC Clinical Trials Centre; Western Clinical School: Medicine (Westmead); NH&MRC Clinical Trials CentreHope, optimism and survival in a randomised trial of chemotherapy for metastatic colorectal cancer, Supportive Care in Cancer, vol.24, 1, 2016,pp 401-408
2005Hormone Replacement Therapy and Breast Cancer Risk in CaliforniaBoyages, John; Coombs, N; Taylor, Richard; Wilcken, Nicholas; Fiorica, James; Western Clinical School: NSW Breast Cancer Institute; Nepean Clinical School: Medicine; School of Public Health: Public Health; Western Clinical School: Medicine (Westmead)Hormone Replacement Therapy and Breast Cancer Risk in California, The Breast Journal 2005, vol.11,(6),2005,pp 410-415
2005Hormone replacement therapy and breast cancer: estimate of risk.Boyages, John; Coombs, N; Taylor, Richard; Wilcken, Nicholas; Western Clinical School: NSW Breast Cancer Institute; Nepean Clinical School: Medicine; School of Public Health: Public Health; Western Clinical School: Medicine (Westmead)Hormone replacement therapy and breast cancer: estimate of risk., e B M J, vol.331,(7512),2005,pp 347-349